Laurie H Sehn

Laurie H Sehn

UNVERIFIED PROFILE

Are you Laurie H Sehn?   Register this Author

Register author
Laurie H Sehn

Laurie H Sehn

Publications by authors named "Laurie H Sehn"

Are you Laurie H Sehn?   Register this Author

100Publications

3427Reads

38Profile Views

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

N Engl J Med 2018 09;379(10):934-947

From Université Lille, Centre Hospitalier Universitaire (CHU), Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille (F.M.), CHU Régional de Nancy, Service d'Hématologie, Vandoeuvre lès Nancy (P.F.), Institut Paoli-Calmettes (R.B.) and Department of Pathology, Institut Paoli-Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM, Centre National de la Recherche Scientifique, Aix-Marseille Université (L.X.), Marseille, Centre Henri Becquerel, Unité 1245 and Département d'Hématologie, Université de Rouen, Rouen (H.T.), Institut d'Hématologie de Basse Normandie, Caen (C.F.), CHU Le Bocage Service d'Hématologie Clinique, Dijon (R.-O.C.), Hôpital Henri Mondor Unité Hémopathies Lymphoïdes, Créteil (C.H.), Centre Hospitalier Départemental Vendée Service d'Onco-Hématologie, La Roche sur Yon (H.M.), Institut Universitaire du Cancer de Toulouse Oncopole Service d'Hématologie, Toulouse (L.Y.), CHU Bordeaux, Service d'Hématologie, Bordeaux (K.B.), Hôpital Saint Louis Service d'Onco-Hématologie, Paris (P.B.), Gustave Roussy Cancer, Villejuif (V.R.), Centre Hospitalier Annecy Genevois Service, Annecy (N.D.), CHU de Nantes-Hôtel Dieu Service d'Hématologie Clinique, Centre de Recherche en Cancerologie et Immunologie, INSERM, Centre National de la Recherche Scientifique, Université de Nantes, Nantes (S.L.G.), Centre Hospitalier Métropole Savoie Service Hématologie, Chambery (G.M.P.), Department of Hematology, CHU Montpellier, University of Montpellier, Montpellier (G.C.), and Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, University of Lyon, Pierre-Benite (G.A.S.) - all in France; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (N.H.F.); the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (M.L.P.); the Department of Medicine, Division of Medical Oncology, University of Washington, Seattle (E.N.L.); Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.W.F.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (N.L.B.); the Department of Hematology, Hospital Universitario de Salamanca and Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, Salamanca (A.M.G.-S.), and the Department of Hematology, Hospital Clinic de Barcelona, Barcelona (A.L.-G.) - both in Spain; CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec (J.-F.L.), and British Columbia Cancer Centre for Lymphoid Cancer, University of British Columbia, Vancouver (L.H.S.) - both in Canada; the Department of Hematology and Oncology, Tokai University Hospital, Kanagawa, Japan (K.A.); Instituto Português de Oncologia Lisboa Francisco Gentil Departamento de Hematologia, Lisbon (M.G.S.); the Department of Hematology, CHU Université Catholique de Louvain Namur, Yvoir (M.A.), and the Department of Hematology, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp (P.Z.) - both in Belgium; the Department of Hematology, National Cancer Center Hospital, Tokyo, Japan (K.T.); and Celgene, Summit, NJ (D.L., J.W.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805104
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805104DOI Listing
September 2018

Editor's introduction.

Authors:
Laurie H Sehn

Best Pract Res Clin Haematol 2018 09 15;31(3):185-186. Epub 2018 Aug 15.

BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2018.08.002DOI Listing
September 2018

Management of relapsed/refractory DLBCL.

Best Pract Res Clin Haematol 2018 09 23;31(3):209-216. Epub 2018 Jul 23.

British Columbia Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, British Columbia, Canada. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216926183005
Publisher Site
http://dx.doi.org/10.1016/j.beha.2018.07.014DOI Listing
September 2018

Double hit lymphoma: do we need a 'double hit' of intensive therapy?

Leuk Lymphoma 2018 08 25;59(8):1767-1768. Epub 2018 Jan 25.

a Centre for Lymphoid Cancer and Division of Medical Oncology , BC Cancer , Vancouver , British Columbia , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1429606DOI Listing
August 2018

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

J Clin Oncol 2018 08 27;36(22):2259-2266. Epub 2018 Mar 27.

Bruce D. Cheson, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC; Neil Chua, University of Alberta, Edmonton, Alberta; Greg Dueck, British Columbia Cancer Agency, Kelowna; Laurie H. Sehn, Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada; Jiri Mayer, University Hospital and Masaryk University, Brno; Marek Trněný, Charles University General Hospital, Prague, Czech Republic; Kamal Bouabdallah, Centre Hospitalier Universitaire Haut-Leveque, Bordeaux; Vincent Delwail, Centre Hospitalier Universitaire de Poitiers, Poitiers; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France; Nathan Fowler, University of Texas, Houston, TX; Oliver Press, Fred Hutchinson Cancer Research Center, Seattle, WA; John G. Gribben, Queen Mary University of London, London; Anne Lennard, Newcastle University, Newcastle upon Tyne, United Kingdom; Pieternella J. Lugtenburg, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; and Günter Fingerle-Rowson, Federico Mattiello, and Andrea Knapp, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.3656
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.3656DOI Listing
August 2018

A tale of two antibodies: obinutuzumab versus rituximab.

Br J Haematol 2018 07 9;182(1):29-45. Epub 2018 May 9.

Centre for Lymphoid Cancer, British Columbia Cancer and the University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15232DOI Listing
July 2018

Introduction to a review series on Hodgkin lymphoma: change is here.

Authors:
Laurie H Sehn

Blood 2018 04 2;131(15):1629-1630. Epub 2018 Mar 2.

Associate Editor, Blood.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-02-824045DOI Listing
April 2018

Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model.

Br J Haematol 2017 11 22;179(3):508-510. Epub 2016 Jul 22.

Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14229DOI Listing
November 2017

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.

J Clin Oncol 2017 Nov 10;35(31):3529-3537. Epub 2017 Aug 10.

Umberto Vitolo, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin; Angelo Michele Carella, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera e Universitaria San Martino-IST, Genoa; Antonio Pinto, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples; Maurizio Martelli, Sapienza University, Rome, Italy; Marek Trněný, Charles University, General Hospital, Prague; David Belada, Charles University Hospital, Hradec Králové, Czech Republic; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; US Oncology Research, The Woodlands, TX; Neil Chua, Cross Cancer Institute, University of Alberta, Edmonton, Alberta; Laurie H. Sehn, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada; Pau Abrisqueta, University Hospital Vall d'Hebron, Barcelona, Spain; Judit Demeter, Semmelweiss University, Budapest, Hungary; Ian Flinn, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Xiaonan Hong, Fudan University Shanghai Cancer Center, Shanghai; Yuan-Kai Shi, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China; Won Seog Kim, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, Republic of Korea; Yoichi Tatsumi, Kinki University Hospital, Osaka, Japan; Mikkel Z. Oestergaard, Günter Fingerle-Rowson, Olivier Catalani, and Tina Nielsen, F. Hoffman-La Roche, Basel, Switzerland; and Michael Wenger, Genentech, South San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.3402DOI Listing
November 2017

Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases.

Br J Haematol 2017 08 3;178(3):442-447. Epub 2017 May 3.

Population Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14702DOI Listing
August 2017

Can histologic transformation of follicular lymphoma be predicted and prevented?

Blood 2017 07 13;130(3):258-266. Epub 2017 Apr 13.

Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-03-691345DOI Listing
July 2017

The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.

Eur J Cancer 2017 04 23;75:195-203. Epub 2017 Feb 23.

Department of Haematology, Peter MacCallum Cancer Centre and University of Melbourne, 305 Grattan Street, Melbourne VIC 3000, Australia; Department of Hematology, Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Hospital Ave, Nedlands WA 6009, Australia; University of Western Australia, 35 Stirling Hwy, Crawley, WA 6009, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.12.029DOI Listing
April 2017

Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma.

Leuk Lymphoma 2017 03 25;58(3):711-714. Epub 2016 Aug 25.

a Division of Medical Oncology , BC Cancer Agency , Vancouver , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1204657DOI Listing
March 2017

Introduction to the review series on T-cell malignancies.

Blood 2017 03 23;129(9):1059-1060. Epub 2017 Jan 23.

Associate Editor, Blood.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-01-741389DOI Listing
March 2017

Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.

Br J Haematol 2017 Jan 14;176(2):210-221. Epub 2016 Oct 14.

Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14392DOI Listing
January 2017

Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience.

Br J Haematol 2017 Jan 21;176(2):234-240. Epub 2016 Oct 21.

Department of Medical Oncology, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14404DOI Listing
January 2017

Diffuse Large B-Cell Lymphoma: Should Limited-Stage Patients Be Treated Differently?

Hematol Oncol Clin North Am 2016 Dec;30(6):1179-1194

Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, 600 West 10th avenue, Vancouver, BC V5Z 4E6, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2016.07.010DOI Listing
December 2016

The Increasing Complexity of Aggressive B-cell Lymphoma.

Authors:
Laurie H Sehn

Hematol Oncol Clin North Am 2016 12;30(6):xiii-xiv

Lymphoma Tumour Group, British Columbia Cancer Agency and the Centre for Lymphoid Cancer, University of British Columbia, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2016.10.001DOI Listing
December 2016

Novel agents in follicular lymphoma: choosing the best target.

Authors:
Laurie H Sehn

Hematology Am Soc Hematol Educ Program 2016 Dec;2016(1):284-292

Centre for Lymphoid Cancer, British Columbia Cancer Agency, and the University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://www.asheducationbook.org/cgi/doi/10.1182/asheducation
Publisher Site
http://dx.doi.org/10.1182/asheducation-2016.1.284DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142508PMC
December 2016

Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.

J Natl Cancer Inst 2016 12 16;108(12). Epub 2016 Dec 16.

Department of Medicine, Mayo Clinic, Rochester, MN (GSN); Department of Internal Medicine, Ohio State University, Columbus, OH (KAB); Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Coordinating Center for Clinical Trials (LB), Division of Cancer Treatment and Diagnosis (RFL), and Center for Cancer Research (WHW), National Cancer Institute, National Institute of Health, Bethesda, MD; Division of Oncology, University of Washington, Seattle WA (DGM); British Colombia Cancer Agency, Vancouver, BC (LHS); Department of Medicine, University of Virginia, Charlottesville, VA (MEW); Department of Medicine, Weil Cornell University, New York, NY (JPL); Department of Medicine, University of Chicago, Chicago, IL (SMS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080361PMC
December 2016

CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.

J Clin Oncol 2016 09 5;34(26):3150-6. Epub 2016 Jul 5.

Norbert Schmitz, Maike Nickelsen, and Bertram Glass, Asklepios Hospital St Georg, Hamburg; Samira Zeynalova, Marita Ziepert, and Markus Loeffler, University of Leipzig, Leipzig; Michael Pfreundschuh, Saarland University Medical School, Homburg, Germany; Roopesh Kansara, Diego Villa, Laurie H. Sehn, David W. Scott, Randy D. Gascoyne, Joseph M. Connors, and Kerry J. Savage, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.6520DOI Listing
September 2016

Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia.

J Clin Oncol 2016 07 6;34(21):2493-500. Epub 2016 Jun 6.

Greg Hapgood, Laurie H. Sehn, Diego Villa, Richard Klasa, Alina S. Gerrie, Tamara Shenkier, David W. Scott, Randy D. Gascoyne, Graham W. Slack, Joseph M. Connors, and Kerry J. Savage, British Columbia Cancer Agency Centre for Lymphoid Cancer; Yvonne Zheng, Cancer Surveillance and Outcomes, Population Oncology; Christina Parsons, James Morris, and Tom Pickles, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.4194DOI Listing
July 2016

Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.

Blood 2016 05 1;127(18):2182-8. Epub 2016 Feb 1.

Department of Pathology and Laboratory Medicine, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-10-676700DOI Listing
May 2016

Introduction to a review series: the paradox of indolent B-cell lymphoma.

Authors:
Laurie H Sehn

Blood 2016 04 17;127(17):2045-6. Epub 2016 Mar 17.

Associate Editor, Blood.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-03-692442DOI Listing
April 2016

Late mortality, secondary malignancy and hospitalisation in teenage and young adult survivors of Hodgkin lymphoma: report of the Childhood/Adolescent/Young Adult Cancer Survivors Research Program and the BC Cancer Agency Centre for Lymphoid Cancer.

Br J Haematol 2016 Mar 5;172(5):757-68. Epub 2016 Jan 5.

Division of Hematology, Oncology and Bone Marrow Transplant, British Columbia Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13903DOI Listing
March 2016

Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma.

Leuk Lymphoma 2016 Feb 19;57(2):276-282. Epub 2015 Jun 19.

d Division of Medical Oncology, University of British Columbia, and the British Columbia Cancer Agency Centre for Lymphoid Cancer , Vancouver , BC , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1055480DOI Listing
February 2016

Rituximab with high-dose methotrexate in primary central nervous system lymphoma.

Am J Hematol 2015 Dec 17;90(12):1149-54. Epub 2015 Nov 17.

Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.24204
Publisher Site
http://dx.doi.org/10.1002/ajh.24204DOI Listing
December 2015

Obinutuzumab in hematologic malignancies: lessons learned to date.

Cancer Treat Rev 2015 Nov 14;41(9):784-92. Epub 2015 Jul 14.

Department of Hematology and UMR CNRS-5235, CHU Montpellier, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2015.07.003DOI Listing
November 2015

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

J Clin Oncol 2015 Oct 17;33(30):3467-74. Epub 2015 Aug 17.

Laurie H. Sehn, Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia; Tara Baetz, Queen's University, Kingston General Hospital, Kingston; Rena Buckstein, Sunnybrook Health Sciences Center; Michael Crump, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Andre Goy and Luis E. Fayad, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Fritz C. Offner, Institute of Hematology and Medical Oncology, University of Bologna; Pier Luigi Zinzani, Institute of Hematology "Seràgnoli" University of Bologna, Bologna; Giovanni Martinelli, European Institute of Oncology, Milano; Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; M. Dolores Caballero, University Hospital of Salamanca, Salamanca, Spain; Ole Gadeberg, Vejle Hospital, Vejle, Denmark; Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center, New York; Jonathan Friedberg, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; Branimir Jadkisic, Clinical Hospital Merkur, University of Zagreb, Zagreb, Croatia; Swaminathan Padmanabhan Iyer, Houston Methodist Cancer Center, Weill Cornell Medical College, Houston, TX; Deniz Sahin and Günter Fingerle-Rowson, Roche, Basel, Switzerland; Akiko Chai, Genentech BioOncology, South San Francisco, CA; Oliver Press, Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.2139DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087315PMC
October 2015

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.

J Clin Oncol 2015 Sep 3;33(26):2848-56. Epub 2015 Aug 3.

David W. Scott, Anja Mottok, Daisuke Ennishi, Pedro Farinha, Susana Ben-Neriah, Robert Kridel, Garrett S. Barry, Christoffer Hother, Pau Abrisqueta, Merrill Boyle, Barbara Meissner, Adele Telenius, Kerry J. Savage, Laurie H. Sehn, Graham W. Slack, Christian Steidl, Joseph M. Connors, and Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; George W. Wright and Louis M. Staudt, National Cancer Institute, Bethesda, MD; and Lisa M. Rimsza, University of Arizona, Tucson, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.2383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554747PMC
September 2015

Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia.

Br J Haematol 2015 May 8;169(4):520-7. Epub 2015 Apr 8.

Department of Medical Oncology, British Columbia Cancer Agency - Vancouver Island Centre, Victoria, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13320DOI Listing
May 2015

Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.

Blood 2015 Jan 11;125(1):22-32. Epub 2014 Dec 11.

Division of Medical Oncology and Department of Pathology, Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2014-05
Publisher Site
http://dx.doi.org/10.1182/blood-2014-05-577189DOI Listing
January 2015

Introduction to a clinical review series on aggressive B-cell lymphoma.

Authors:
Laurie H Sehn

Blood 2015 Jan 11;125(1):1-2. Epub 2014 Dec 11.

Associate Editor, Blood.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-09-594580DOI Listing
January 2015

CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.

Br J Haematol 2014 Dec 19;167(5):608-17. Epub 2014 Aug 19.

Centre for Lymphoid Cancers, British Columbia Cancer Agency, Vancouver, BC, Canada; Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13085DOI Listing
December 2014

Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis.

Blood 2014 Jun 8;123(23):3567-73. Epub 2014 Apr 8.

Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-12-541078DOI Listing
June 2014

Diffuse large B-cell lymphoma: one treatment no longer fits all.

Authors:
Laurie H Sehn

Oncology (Williston Park) 2014 Apr;28(4):334-6

View Article

Download full-text PDF

Source
April 2014

Effect of place of residence and treatment on survival outcomes in patients with diffuse large B-cell lymphoma in British Columbia.

Oncologist 2014 Mar 25;19(3):283-90. Epub 2014 Feb 25.

Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplantation Program of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0343DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958457PMC
March 2014

Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma.

Authors:
Laurie H Sehn

Hematology Am Soc Hematol Educ Program 2012 ;2012:402-9

Division of Medical Oncology and the Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2012.1.402DOI Listing
June 2013

Chemotherapy alone for localized diffuse large B-cell lymphoma.

Authors:
Laurie H Sehn

Cancer J 2012 Sep-Oct;18(5):421-6

Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e31826c5907DOI Listing
April 2013

Treatment and outcomes of primary breast lymphoma.

Clin Breast Cancer 2012 Dec 25;12(6):412-9. Epub 2012 Sep 25.

Radiation Therapy Program, BC Cancer Agency, Vancouver and Victoria, BC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2012.07.006DOI Listing
December 2012

Pathogenesis of follicular lymphoma.

J Clin Invest 2012 Oct 1;122(10):3424-31. Epub 2012 Oct 1.

Center for Lymphoid Cancer, BC Cancer Agency, Department of Pathology and Laboratory Medicine, and Division of Medical Oncology, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI63186DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461914PMC
October 2012

Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy.

Cancer 2012 Sep 17;118(17):4156-65. Epub 2012 Jan 17.

Department of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.26687
Publisher Site
http://dx.doi.org/10.1002/cncr.26687DOI Listing
September 2012

International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era.

J Clin Oncol 2012 Sep 6;30(27):3383-8. Epub 2012 Aug 6.

British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.41.0910DOI Listing
September 2012

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.

Blood 2012 May 20;119(22):5118-25. Epub 2012 Mar 20.

British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-02-408773DOI Listing
May 2012

Follicular lymphoma: prognostic factors, conventional therapies, and hematopoietic cell transplantation.

Biol Blood Marrow Transplant 2012 Jan;18(1 Suppl):S82-91

Division of Medical Oncology and Centre for Lymphoid Cancer, British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2011.11.012DOI Listing
January 2012

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome.

Blood 2011 Oct 26;118(17):4585-90. Epub 2011 Aug 26.

Department of Medical Oncology, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-07-365932DOI Listing
October 2011